Johnson & Johnson Inc. does not expect a biosimilar rival to its blockbuster tumor necrosis factor (TNF) inhibitor Remicade (infliximab) will launch in the US this year, despite the FDA approval of Celltrion Inc.'s Inflectra (infliximab-dyyb) April 5, and it remains comfortable with the growth outlook for pharmaceuticals.
JnJ Not Sweating Remicade Biosimilar Approval
Johnson & Johnson Inc. does not expect a biosimilar rival to its blockbuster tumor necrosis factor (TNF) inhibitor Remicade (infliximab) will launch in the US this year, despite the FDA approval of Celltrion Inc.'s Inflectra (infliximab-dyyb) April 5, and it remains comfortable with the growth outlook for pharmaceuticals.
More from Alimentary/Metabolic
• By
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
More from Therapy Areas
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.